Organon (OGN) Insider Robert Essner Buys $240K of Stock

Robert Essner joined a wave of buying at Organon & Co. (NYSE: OGN) on June 12, 2026. He purchased 17,857 shares at a price of $13.44 each, bringing the total value of his trade to $239,998.08. This transaction follows a pattern of recent insider activity at the New Jersey-based healthcare firm.

This purchase was part of a coordinated series of trades. Along with Essner, five other individuals — Alan Ezekowitz, Helene Gayle, Rochelle Lazarus, Cynthia Patton, and Deborah Leone — each bought exactly 17,857 shares on June 12, 2026. Every one of these transactions occurred at the $13.44 price point and was not conducted under a Rule 10b5-1 trading plan, which is a setup some insiders use to schedule trades automatically.

Organon's stock has shown strength lately. On Tuesday, shares were priced at $13.44, putting the company within striking distance of its 52-week high of $13.79. This is a significant climb from its low of $5.69 over the past year. The stock is also trending above its 50-day moving average of $13.63 and its 200-day moving average of $10.59. Investors often watch these averages to see if a stock's momentum is holding up.

Recent Earnings

Organon & Co. reported revenue of $6.13 billion in its most recent financial period, though it saw a slight revenue dip of 2.3%. The company's profitability is reflected in its 3.41% net margin and a return on equity of 24.04%, which measures how well it generates profit from shareholder investments. The firm is expected to release its next set of financial results on November 9, 2026.

Dividend

For those focused on income, the company pays an annual dividend of $0.08 per share. This works out to a dividend yield of 0.58%. With a payout ratio of 10.26%, the company uses about a tenth of its earnings to cover these payments to shareholders.

Insider Buying and Selling at Organon & Co.

The cluster of buying on June 12, 2026, suggests a shared sentiment among the company's leadership. Alan Ezekowitz, Helene Gayle, Rochelle Lazarus, Cynthia Patton, and Deborah Leone all acquired 17,857 shares at $13.44. These trades, combined with Robert Essner's purchase, represent a collective investment of approximately $1.44 million by this group in a single day.

Healthcare Solutions for Women

Organon & Co. focuses on women's health, offering a range of products from contraception and fertility treatments like Nexplanon and NuvaRing to biosimilars for immunology and oncology. The company was spun off to concentrate specifically on these therapies alongside medicines for respiratory issues and dermatology. These recent insider buys suggest those closest to the company see value at the current price levels as they expand their reach globally.

Investors will likely keep a close eye on the November 9, 2026, earnings date to see if the company's financial results justify this level of internal confidence. While these insider purchases are documented in public filings, they represent a moment in time and may not reflect the current outlook of the individuals involved.